MedTrace Logo

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Conditions

  • Graves Disease

Interventions

BIOLOGICAL

MER511 (SC) for MAD

Participants will receive multiple ascending doses of MER511 via SC administration assigned for their cohort on Day 1 and Day 29

BIOLOGICAL

Placebo comparator (SC) for MAD

Participants will receive multiple doses of placebo via SC administration assigned for their cohort on Day 1 and Day 29

BIOLOGICAL

MER511 (IV)

Participants will receive a single dose of MER511 on Day 1

BIOLOGICAL

Placebo comparator (IV)

Participants will receive a single dose of Placebo on Day 1

BIOLOGICAL

MER511 (SC)

Participants will receive a single dose of MER511 on Day 1

BIOLOGICAL

Placebo comparator (SC)

Participants will receive a single dose of Placebo on Day 1

Sponsors & Collaborators

  • Merida Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-19
Primary Completion
2028-07-24
Completion
2028-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07305818 on ClinicalTrials.gov